Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1/PRAME DC Vaccine in AML
NCT02405338Phase 2Completed
- Sponsor
- Medigene AG
- Start
- Mar 2015
- Primary completion
- Nov 2019
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of FDC101 in acute myeloid leukemia (AML), sponsored by Medigene AG. Started Mar 2015; status: completed.
02
Drugs
FDC101
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02405338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02405338.